Torrent Pharma declares ₹29 interim dividend; Q3 FY26 consolidated profit at ₹635 Cr.
Torrent Pharmaceuticals Limited announced its Q3 FY26 results. The company reported a consolidated net profit of ₹635 crore, up from ₹503 crore in Q3 FY25. Consolidated revenue from operations rose to ₹3,303 crore from ₹2,809 crore. An interim dividend of ₹29 per share was declared, payable around March 6, 2026.
The financial results show significant year-on-year growth in both revenue and profit. The declaration of a substantial interim dividend and progress in the acquisition of JB Pharma are material events for the company.
The company reported increased profits and revenues for the quarter and nine months ended December 31, 2025, compared to the previous year. The declaration of an interim dividend also positively impacts shareholder returns.
Torrent Pharmaceuticals Limited announced its financial results for the quarter and nine months ended December 31, 2025. The Board of Directors, in their meeting held on February 13, 2026, approved the audited standalone and unaudited consolidated financial results.
The company declared an interim dividend of ₹29 per equity share (580%), with the payment expected around March 6, 2026.
For the quarter ended December 31, 2025, Torrent Pharma reported a consolidated net profit of ₹635 crore, an increase from ₹503 crore in the same quarter of the previous year. Total consolidated revenue from operations for the quarter stood at ₹3,303 crore, up from ₹2,809 crore year-on-year.
The standalone net profit for the quarter was ₹577 crore, compared to ₹485 crore in the prior year's corresponding quarter. Standalone revenue from operations was ₹2,599 crore, an increase from ₹2,377 crore.
During the period, the company also made significant progress in its acquisition of a controlling stake in J.B. Chemicals & Pharmaceuticals Limited (JB Pharma), with the acquisition of a 46.39% stake completed on January 21, 2026, and further acquisitions from employees on January 23, 2026, and February 3, 2026. The company is proceeding with obtaining approvals for the proposed merger of JB Pharma, which will involve issuing 51 equity shares of Torrent Pharma for every 100 equity shares of JB Pharma. Expenses related to this acquisition have been charged to the Profit and Loss statement.
What to do with a filing like this
Torrent Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Torrent Pharmaceuticals Limited. Read the original for the full detail.